Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer
- Authors:
- Masataka Sawaki
- Ai Idota
- Mari Ichikawa
- Naomi Gondo
- Akiyo Horio
- Naoto Kondo
- Masaya Hattori
- Takashi Fujita
- Yasushi Yatabe
- Hiroji Iwata
View Affiliations
Affiliations: Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 464‑8681, Japan, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Aichi 464‑8681, Japan
- Published online on: July 10, 2014 https://doi.org/10.3892/ol.2014.2333
-
Pages:
1707-1712
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Axillary lymph node (LN) metastasis is one of the most important prognostic factors for the survival of breast cancer. The correlation between LN metastasis and the tumor (T) category has previously been investigated in certain case series. At present, the initial treatment approach is to define the intrinsic subtype, as it is significant in determining medical treatments, as well as being a prognostic factor. However, the intrinsic subtype is not known to predict the frequency of LN metastasis. The aim of the present study was to evaluate the frequency of LN metastasis with regard to tumor size according to the intrinsic subtype. In total, 654 patients with primary breast cancer were evaluated who underwent surgical resection between 2010 and 2011 at the Aichi Cancer Center Hospital (Nagoya, Aichi). The clinical and pathological data were analyzed for patients who underwent an axillary LN dissection or a sentinel LN biopsy for primary breast cancer. The intrinsic subtype of the primary tumors was classified using immunohistochemical staining of thin, paraffin‑embedded sections. In total, 157 (24.0%) of the 654 patients exhibited LN metastasis, and according to the primary tumor category, a larger tumor size was found to correlate with a higher proportion of LN positivity, as well as with the luminal A subtypes (n=364). In luminal B subtypes (n=110), T1a (n=2), T1b (n=12), T1c (n=55), T2 (n=34), and T3 (n=2) exhibited 50, 8.3, 38.2, 55.9 and 50% LN positivity, respectively. In luminal‑human epidermal growth factor receptor 2 (HER2) subtypes (n=46), T1c (n=17), T2 (n=10), and T3 (n=1) exhibited 40.1, 60 and 100% LN positivity, respectively. In HER2 subtypes (n=53), T1a (n=6), T1b (n=4), T1c (n=15), and T2 (n=10) exhibited 16.7, 25, 46.7 and 60% LN positivity, respectively. In triple‑negative subtypes (n=81), T1b (n=15), T1c (n=29), T2 (n=20), and T3 (n=2) exhibited 26.7, 24.1, 50 and 50% LN positivity, respectively. In conclusion, the intrinsic subtype is significant in predicting the frequency of LN metastasis with regard to tumor size.
View Figures |
Figure 1
|
|
Figure 2
|
|
Figure 3
|
|
Figure 4
|
|
Figure 5
|
|
Figure 6
|
|
Figure 7
|
View References
1
|
Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/.
Accessed June 26, 2014
|
2
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members. Strategies for
subtypes - dealing with the diversity of breast cancer: highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747.
2011.
|
3
|
Cody HS III and Houssami N: Axillary
management in breast cancer: what’s new for 2012? Breast.
21:411–415. 2012.
|
4
|
Silverstein MJ, Gierson ED, Waisman JR,
Colburn WJ and Gamagami P: Predicting axillary node positivity in
patients with invasive carcinoma of the breast by using a
combination of T category and palpability. J Am Coll Surg.
180:700–704. 1995.
|
5
|
Sobin LH and Wittekind CH: Breast tumors.
TNM Classification of Malignant Tumours. 6th edition. UICC,
Wiley-Liss; New York, NY: pp. 131–142. 2002
|
6
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.
|
7
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.
|
8
|
Hammond ME, Hayes DF, Dowsett M, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for immunohistochemical
testing of estrogen and progesterone receptors in breast cancer. J
Clin Oncol. 28:2784–2795. 2010.
|
9
|
Wolff AC, Hammond ME, Schwartz JN, et al;
American Society of Clinical Oncology; College of American
Pathologists. American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007.
|
10
|
Penault-Llorca F, André F, Sagan C, et al:
Ki67 expression and docetaxel efficacy in patients with estrogen
receptor-positive breast cancer. J Clin Oncol. 27:2809–2815.
2009.
|
11
|
Dowsett M, Nielsen TO, A’Hern R, et al;
International Ki-67 in Breast Cancer Working Group. Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664.
2011.
|
12
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000.
|
13
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001.
|
14
|
Arpino G, Generali D, Sapino A, et al:
Gene expression profiling in breast cancer: a clinical perspective.
Breast. 22:109–120. 2013.
|
15
|
Millikan RC, Newman B, Tse CK, et al:
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat.
109:123–139. 2008.
|
16
|
Phipps AI, Buist DS, Malone KE, et al:
Reproductive history and risk of three breast cancer subtypes
defined by three biomarkers. Cancer Causes Control. 22:399–405.
2011.
|
17
|
Nguyen PL, Taghian AG, Katz MS, et al:
Breast cancer subtype approximated by estrogen receptor,
progesterone receptor, and HER-2 is associated with local and
distant recurrence after breast-conserving therapy. J Clin Oncol.
26:2373–2378. 2008.
|
18
|
Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009.
|
19
|
Morrison DH, Rahardja D, King E, Peng Y
and Sarode VR: Tumour biomarker expression relative to age and
molecular subtypes of invasive breast cancer. Br J Cancer.
107:382–387. 2012.
|
20
|
Yoshihara E, Smeets A, Laenen A, et al:
Predictors of axillary lymph node metastases in early breast cancer
and their applicability in clinical practice. Breast. 22:357–361.
2012.
|
21
|
Ravdin PM, De Laurentiis M, Vendely T and
Clark GM: Prediction of axillary lymph node status in breast cancer
patients by use of prognostic indicators. J Natl Cancer Inst.
86:1771–1775. 1994.
|
22
|
NCCN guideline 2013. ver2. 2013,
http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Accessed April 17, 2013
|